Updates from the 48th Annual San Antonio Breast Cancer Symposium

- Novel Therapy for Adjuvant Hormone Receptor Positive Breast Cancer - Antibody Drug Conjugates in First Line Metastatic Hormone Receptor Positive Breast Cancer - Tailoring First Line Therapy in Metastatic HER2 Positive Breast Cancer - Integration & Sequencing of Novel Oral Selective Estrogen Receptor Degraders (SERDs) in Metastatic Hormone Receptor Positive Breast Cancer - Deescalating Therapy in Low-Risk Ductal Carcinoma In Situ (DCIS) - Questions for Our Panel of Experts